INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Phase 1 Completed 50 enrolled Incyte Corporation

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of parsaclisib when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or refractory B-cell lymphoma.

Timeline

Start: 2018-07-02
Primary completion: 2022-06-27
Completion: 2022-06-27

Publications

Sancho JM, Abrisqueta P, Kumar A, Cordoba R, Tani M, Langmuir P, Rappold E, Liu T, Lopez-Guillermo A. Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL-112). Leuk Lymphoma. 2024 Jul;65(7):911-921. doi: 10.1080/10428194.2024.2331626. Epub 2024 Apr 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Parsaclisib	Small molecule	—	Oral
Background	Bendamustine	Small molecule	—	Intravenous
Background	Ibrutinib	Small molecule	—	Oral
Background	Rituximab	Monoclonal antibody	—	Intravenous

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Summary

Timeline

Publications

Drugs

Indications